{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:04:14Z","timestamp":1786993454547,"version":"build-2736575974"},"reference-count":54,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,2]],"date-time":"2024-03-02T00:00:00Z","timestamp":1709337600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.jtha.2024.02.016","type":"journal-article","created":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T11:46:34Z","timestamp":1709639194000},"page":"1591-1604","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Comprehensive domain-specific analysis and immunoglobulin G profiling of anti\u2013factor VIII antibodies using a bead-based multiplex immunoassay"],"prefix":"10.1016","volume":"22","author":[{"given":"Behnaz","family":"Pezeshkpoor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Cristin","family":"Berkemeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Herbst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thilo","family":"Albert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Oldenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl 1","key":"10.1016\/j.jtha.2024.02.016_bib1","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1053\/j.seminhematol.2003.11.016","article-title":"Environmental and genetic factors influencing inhibitor development","volume":"41","author":"Oldenburg","year":"2004","journal-title":"Semin Hematol"},{"key":"10.1016\/j.jtha.2024.02.016_bib2","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/0140-6736(92)90874-3","article-title":"Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs","volume":"339","author":"Ehrenforth","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2024.02.016_bib3","doi-asserted-by":"crossref","first-page":"563","DOI":"10.3389\/fimmu.2020.00563","article-title":"Prevalence and incidence of non-neutralizing antibodies in congenital hemophilia A- a systematic review and meta-analysis","volume":"11","author":"Abdi","year":"2020","journal-title":"Front Immunol"},{"issue":"suppl 6","key":"10.1016\/j.jtha.2024.02.016_bib4","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1365-2516.2006.01361.x","article-title":"Genetic risk factors for inhibitors to factors VIII and IX","volume":"12","author":"Oldenburg","year":"2006","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.02.016_bib5","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/oxfordjournals.bmb.a069445","article-title":"Assessment of clotting efficiency","volume":"11","author":"Biggs","year":"1955","journal-title":"Br Med Bull"},{"key":"10.1016\/j.jtha.2024.02.016_bib6","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1055\/s-0029-1245107","article-title":"Improvements in factor VIII inhibitor detection: from Bethesda to Nijmegen","volume":"35","author":"Verbruggen","year":"2009","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.jtha.2024.02.016_bib7","first-page":"875","article-title":"Letter: measurement of mild factor VIII inhibitors in Bethesda units","volume":"34","author":"Kasper","year":"1975","journal-title":"Thromb Diath Haemorrh"},{"key":"10.1016\/j.jtha.2024.02.016_bib8","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1055\/s-0037-1616765","article-title":"The type of factor VIII deficient plasma used influences the performance of the Nijmegen modification of the Bethesda assay for factor VIII inhibitors","volume":"86","author":"Verbruggen","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.02.016_bib9","doi-asserted-by":"crossref","first-page":"e116","DOI":"10.1111\/hae.13434","article-title":"Reagent substitutions in the Centers for Disease Control and Prevention Nijmegen-Bethesda assay for factor VIII inhibitors","volume":"24","author":"Miller","year":"2018","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.02.016_bib10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/ejh.13339","article-title":"Clinical utility and impact of the use of the chromogenic vs one-stage factor activity assays in haemophilia A and B","volume":"104","author":"Marlar","year":"2020","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jtha.2024.02.016_bib11","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1046\/j.1365-2141.1996.d01-1705.x","article-title":"High incidence of anti-FVIII antibodies against non-coagulant epitopes in haemophilia A patients: a possible role for the half-life of transfused FVIII","volume":"93","author":"Dazzi","year":"1996","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2024.02.016_bib12","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1182\/blood-2015-10-675512","article-title":"FVIII-binding IgG modulates FVIII half-life in patients with severe and moderate hemophilia A without inhibitors","volume":"128","author":"Hofbauer","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.02.016_bib13","doi-asserted-by":"crossref","first-page":"e406","DOI":"10.1111\/hae.12508","article-title":"Are low-density lipoprotein receptor-related protein 1 or non-neutralizing antibodies predictors of FVIII in\u00a0vivo recovery in haemophilia A patients?","volume":"20","author":"Clere","year":"2014","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.02.016_bib14","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1111\/j.1538-7836.2012.04645.x","article-title":"Low-titre inhibitors, undetectable by the Nijmegen assay, reduce factor VIII half-life after immune tolerance induction","volume":"10","author":"Dardikh","year":"2012","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.02.016_bib15","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1182\/blood-2014-09-598268","article-title":"Affinity of FVIII-specific antibodies reveals major differences between neutralizing and nonneutralizing antibodies in humans","volume":"125","author":"Hofbauer","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.02.016_bib16","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1182\/bloodadvances.2021005745","article-title":"Nonneutralizing FVIII-specific antibody signatures in patients with hemophilia A and in healthy donors","volume":"6","author":"Schweiger","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2024.02.016_bib17","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1182\/blood-2016-06-720086","article-title":"Nonneutralizing antibodies against factor VIII and risk of inhibitor development in severe hemophilia A","volume":"129","author":"Cannav\u00f2","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.02.016_bib18","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/hae.14669","article-title":"Methods for anti-factor VIII antibody levels in haemophilia A patients \u2013 validation of a multiplex immunoassay and comparability with assays measuring non-neutralising and neutralising antibodies (inhibitors)","volume":"29","author":"Martin","year":"2023","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.02.016_bib19","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s12016-009-8119-0","article-title":"Characteristics, mechanisms of action, and epitope mapping of anti-factor VIII antibodies","volume":"37","author":"Lavigne-Lissalde","year":"2009","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jtha.2024.02.016_bib20","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1160\/TH07-08-0497","article-title":"Simultaneous detection and epitope mapping of anti-factor VIII antibodies","volume":"99","author":"Lavigne-Lissalde","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.02.016_bib21","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1160\/TH10-10-0668","article-title":"Prevalence and epitope specificity of non-neutralising antibodies in a large cohort of haemophilia A patients without inhibitors","volume":"105","author":"Lebreton","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.02.016_bib22","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/jth.12768","article-title":"Hemophilia Inhibitor Research Study Investigators. Characterization of the anti-factor VIII immunoglobulin profile in patients with hemophilia A by use of a fluorescence-based immunoassay","volume":"13","author":"Boylan","year":"2015","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.02.016_bib23","doi-asserted-by":"crossref","first-page":"5785","DOI":"10.1182\/bloodadvances.2020002731","article-title":"The prospective hemophilia inhibitor PUP Study reveals distinct antibody signatures prior to FVIII inhibitor development","volume":"4","author":"Reipert","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2024.02.016_bib24","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1111\/jth.15665","article-title":"Investigating potential mechanisms underlying FVIII inhibition in acquired hemophilia A associated with mRNA COVID-19 vaccines","volume":"20","author":"Hirsiger","year":"2022","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.02.016_bib25","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/j.jtha.2023.03.011","article-title":"Antidrug antibodies against the polyethylene glycol moiety inhibit the procoagulant activity of therapeutic polyethylene glycolated factor VIII","volume":"21","author":"Pezeshkpoor","year":"2023","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.02.016_bib26","doi-asserted-by":"crossref","first-page":"6614","DOI":"10.1038\/s41598-021-86035-2","article-title":"Accurate SARS-CoV-2 seroprevalence surveys require robust multi-antigen assays","volume":"11","author":"Fotis","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.jtha.2024.02.016_bib27","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1159\/000351459","article-title":"Luminex\u00ae and its applications for solid organ transplantation, hematopoietic stem cell transplantation, and transfusion","volume":"40","author":"Lachmann","year":"2013","journal-title":"Transfus Med Hemother"},{"key":"10.1016\/j.jtha.2024.02.016_bib28","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1515\/cclm-2014-1037","article-title":"Comparison of the bead-based simultaneous analysis of specific platelet antibodies assay (SASPA) and Pak Lx Luminex technology with the monoclonal antibody immobilization of platelet antigens assay (MAIPA) to detect platelet\u00a0alloantibodies","volume":"53","author":"Rockenbauer","year":"2015","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.jtha.2024.02.016_bib29","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.3390\/diagnostics11091630","article-title":"Trends in multiplex immunoassays for in\u00a0vitro diagnostics and point-of-care testing","volume":"11","author":"Vashist","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.jtha.2024.02.016_bib30","first-page":"347","article-title":"Familial multiple coagulation factor deficiencies (FMCFDs) in a large cohort of patients\u2013a single-center experience in genetic diagnosis","volume":"10","author":"Preisler","year":"2021","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.jtha.2024.02.016_bib31","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1365-2516.2008.01924.x","article-title":"Diagnosis and quantification of factor VIII inhibitors","volume":"16","author":"Verbruggen","year":"2010","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.02.016_bib32","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jbbm.2005.12.008","article-title":"RF cloning: a restriction-free method for inserting target genes into plasmids","volume":"67","author":"van den Ent","year":"2006","journal-title":"J\u00a0Biochem Biophys Methods"},{"key":"10.1016\/j.jtha.2024.02.016_bib33","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1007\/s00277-019-03691-1","article-title":"In silico and in\u00a0vitro evaluation of the impact of mutations in non-severe haemophilia A patients on assay discrepancies","volume":"98","author":"Pezeshkpoor","year":"2019","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jtha.2024.02.016_bib34","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/hae.14885","article-title":"Two-center validation of assays for the detection of binding and neutralizing anti-factor VIII antibodies","volume":"30","author":"M\u00fcller","year":"2024","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.02.016_bib35","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.jpba.2008.09.020","article-title":"Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products","volume":"48","author":"Shankar","year":"2008","journal-title":"J\u00a0Pharm Biomed Anal"},{"key":"10.1016\/j.jtha.2024.02.016_bib36","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2012-07-444877","article-title":"Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients","volume":"121","author":"Whelan","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.02.016_bib37","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1111\/jth.12259","article-title":"Hemophilia Inhibitor Research Study Investigators. Comparison of clot-based, chromogenic and fluorescence assays for measurement of factor VIII inhibitors in the US Hemophilia Inhibitor Research Study","volume":"11","author":"Miller","year":"2013","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.02.016_bib38","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1111\/j.1365-2516.2010.02272.x","article-title":"Domain specificity of factor VIII inhibitors during immune tolerance induction in patients with haemophilia A","volume":"16","author":"van Helden","year":"2010","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.02.016_bib39","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1160\/TH14-01-0101","article-title":"Epitope mapping via selection of anti-FVIII antibody-specific phage-presented peptide ligands that mimic the antibody binding sites","volume":"113","author":"Kahle","year":"2015","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.02.016_bib40","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/hae.13105","article-title":"Anti-factor VIII antibodies in brothers with haemophilia A share similar characteristics","volume":"23","author":"Kahle","year":"2017","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.02.016_bib41","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1182\/blood.V91.7.2347","article-title":"A\u00a0human alloantibody interferes with binding of factor IXa to the factor VIII light chain","volume":"91","author":"Fijnvandraat","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.02.016_bib42","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1182\/blood.V74.5.1618.1618","article-title":"Localization of epitopes for human factor VIII inhibitor antibodies by immunoblotting and antibody neutralization","volume":"74","author":"Scandella","year":"1989","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.02.016_bib43","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1182\/blood.V86.5.1811.bloodjournal8651811","article-title":"Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid-binding site","volume":"86","author":"Scandella","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.02.016_bib44","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1182\/blood.V82.6.1767.1767","article-title":"A\u00a0recombinant factor VIII A2 domain polypeptide quantitatively neutralizes human inhibitor antibodies that bind to A2","volume":"82","author":"Scandella","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.02.016_bib45","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1160\/TH06-09-0510","article-title":"Molecular characterization of human B domain-specific anti-factor VIII monoclonal antibodies generated in transgenic mice","volume":"98","author":"Lavigne-Lissalde","year":"2007","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.02.016_bib46","doi-asserted-by":"crossref","first-page":"25774","DOI":"10.1074\/jbc.M002007200","article-title":"Factor VIII C2 domain contains the thrombin-binding site responsible for thrombin-catalyzed cleavage at Arg1689","volume":"275","author":"Nogami","year":"2000","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jtha.2024.02.016_bib47","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0180456","article-title":"An in silico and in\u00a0vitro approach to elucidate the impact of residues flanking the cleavage scissile bonds of FVIII","volume":"12","author":"Pezeshkpoor","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jtha.2024.02.016_bib48","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/j.1365-2516.2008.01694.x","article-title":"Factor VIII genotype and inhibitor development in patients with haemophilia A: highest risk in patients with splice site mutations","volume":"14","author":"Boekhorst","year":"2008","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.02.016_bib49","doi-asserted-by":"crossref","first-page":"204","DOI":"10.5045\/br.2019.54.3.204","article-title":"The prevalence and risk factors of inhibitor development of FVIII in previously treated patients with hemophilia A","volume":"54","author":"Kim","year":"2019","journal-title":"Blood Res"},{"key":"10.1016\/j.jtha.2024.02.016_bib50","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/hae.12646","article-title":"A\u00a0longitudinal evaluation of anti-FVIII antibodies demonstrated IgG4 subclass is mainly correlated with high-titre inhibitor in haemophilia A patients","volume":"21","author":"Montalv\u00e3o","year":"2015","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.02.016_bib51","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1182\/blood-2013-09-527275","article-title":"High-resolution mapping of epitopes on the C2 domain of factor VIII by analysis of point mutants using surface plasmon resonance","volume":"123","author":"Nguyen","year":"2014","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.jtha.2024.02.016_bib52","first-page":"S29","article-title":"BAX 855, a PEGylated rFVIII\u00a0product with prolonged half-life. Development, functional and\u00a0structural characterisation","volume":"32","author":"Turecek","year":"2012","journal-title":"Hamostaseologie"},{"key":"10.1016\/j.jtha.2024.02.016_bib53","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1182\/blood-2012-01-407494","article-title":"A\u00a0novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models","volume":"121","author":"Stennicke","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.02.016_bib54","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1007\/s40265-021-01615-w","article-title":"Efmoroctocog alfa: a review in haemophilia A","volume":"81","author":"Frampton","year":"2021","journal-title":"Drugs"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153878362400120X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153878362400120X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T19:47:21Z","timestamp":1718826441000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S153878362400120X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":54,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S153878362400120X"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2024.02.016","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comprehensive domain-specific analysis and immunoglobulin G profiling of anti\u2013factor VIII antibodies using a bead-based multiplex immunoassay","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2024.02.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}]}}